Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Current Assets (2016 - 2025)

Historic Current Assets for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $3.4 million.

  • Ernexa Therapeutics' Current Assets fell 2856.24% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 2856.24%. This contributed to the annual value of $2.4 million for FY2024, which is 7549.74% down from last year.
  • According to the latest figures from Q3 2025, Ernexa Therapeutics' Current Assets is $3.4 million, which was down 2856.24% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Current Assets peaked at $51.9 million during Q2 2021, and registered a low of $2.2 million during Q1 2025.
  • Its 5-year average for Current Assets is $12.1 million, with a median of $6.8 million in 2023.
  • In the last 5 years, Ernexa Therapeutics' Current Assets skyrocketed by 82224.55% in 2021 and then crashed by 8225.31% in 2023.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Current Assets stood at $25.8 million in 2021, then plummeted by 46.89% to $13.7 million in 2022, then decreased by 29.84% to $9.6 million in 2023, then plummeted by 75.5% to $2.4 million in 2024, then soared by 43.66% to $3.4 million in 2025.
  • Its Current Assets stands at $3.4 million for Q3 2025, versus $4.8 million for Q2 2025 and $2.2 million for Q1 2025.